Geron Q3 2025 RYTELO revenue $47.2M; net loss narrows to $18.4M; FY25 opex guidance lowered

GERON CORP

2025-Q3 EPS reported -$0.08 revenue$135,866,000

RYTELO net product revenue $47.2M in Q3 2025 (vs $28.2M in Q3 2024); demand down 3% QoQ.
Net loss $18.4M ($0.03/share) compared to $26.4M ($0.04/share) in Q3 2024.
Completed enrollment of 320 patients in Phase 3 IMpactMF trial for imetelstat in myelofibrosis.
FY 2025 operating expense guidance reduced to $250M-260M from prior $270M-285M.
Appointed Ahmed ElNawawi as EVP, Chief Commercial Officer; three other executives added.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.